目的 分析接受卵巢癌 (OC) 化疗的患者报告结果 (PRO) 的波动及其与外周血细胞因子的关系。通过 M.D. Anderson 症状清单-卵巢癌 (MDASI-OC) 前瞻性测量 PRO 负担）在化疗前的基线，化疗期间和化疗后第 7 天、第 14 天和第 20 天每天收集细胞因子。在基线、出院前几天和 PCD 20 收集细胞因子。使用 Pearson 相关性来探索之间的关联外周血PROs和细胞因子水平。比较新辅助化疗(NACT)组(n=20)和术后辅助化疗(PAC)组(n=7)的前8位症状。化疗前，NACT组的疲劳和食欲不振平均评分高于PAC组。化疗后，疼痛、恶心、呕吐、睡眠不安、食欲不振、便秘在PCD 2-6期间达到峰值；而在 PCD 2-13 期间，疲劳和麻木或刺痛感仍然处于较高水平。到 PCD 20，睡眠障碍和疲劳的平均分数显着增加，特别是在 NACT 组中；与此同时，其他症状评分下降并恢复到基线水平。此外，疼痛、疲劳和食欲不振的纵向波动与白细胞介素6和干扰素γ的循环水平呈正相关（p<0.05）。MDASI-OC对于证明整个化疗过程中症状负担的波动是可行且适应性强的。此外，症状随细胞因子水平的变化可以为探索生化病因学机制提供线索。© 2025。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To analyze the fluctuations of patient-reported outcomes (PROs) and their relationships with cytokines in the peripheral blood of patients undergoing chemotherapy for ovarian cancer (OC).PROs burden was prospectively measured by the M.D. Anderson Symptom Inventory-Ovarian Cancer (MDASI-OC) at baseline before chemotherapy, on a daily basis during and post-chemotherapy days (PCD) 7, 14, and 20. Cytokines were collected at baseline, days prior to hospital discharge and PCD 20. Pearson correlation was used to explore the associations between PROs and cytokines levels in peripheral blood.The top 8 rated symptoms were compared between the neoadjuvant chemotherapy (NACT) group (n=20) and the postoperative adjuvant chemotherapy (PAC) group (n=7). Before chemotherapy, the mean scores of fatigue and lack of appetite in the NACT group were higher than those in the PAC group. After chemotherapy, pain, nausea, vomiting, disturbed sleep, lack of appetite, and constipation increased to peak during PCD 2-6; while, fatigue and numbness or tingling remained at high levels over PCD 2-13. By PCD 20, disturbed sleep and fatigue showed a significant increase in mean scores, particularly in the NACT group; while, other symptom scores decreased and returned to baseline levels. Additionally, the longitudinal fluctuations in pain, fatigue, and lack of appetite were positively associated with circulating levels of interleukin-6 and interferon gamma (p<0.05).MDASI-OC was feasible and adaptable for demonstrating the fluctuations of symptom burden throughout chemotherapy course. Moreover, symptoms changing along with cytokines levels could provide clues for exploring mechanism underlying biochemical etiology.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.